Ultragenyx Pharmaceutical Inc.
RARE
$26.84
$0.542.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -22.52% | 3.49% | -35.12% | 12.65% | 11.53% |
| Total Depreciation and Amortization | -11.11% | -7.88% | -1.72% | -2.74% | 1.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.13% | -10.06% | -5.24% | -32.44% | 17.95% |
| Change in Net Operating Assets | 8.93% | -97.42% | 77.95% | -233.35% | 0.03% |
| Cash from Operations | -18.67% | -25.86% | -36.46% | -40.68% | 12.96% |
| Capital Expenditure | 0.00% | -475.46% | 20.96% | -22.45% | 68.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -139.67% | -169.46% | 143.25% | 17.68% | 23.92% |
| Cash from Investing | -140.83% | -170.48% | 142.53% | 17.52% | 27.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -25.57% | -99.95% | -78.27% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 13,285.13% | -99.98% | -78.27% | 370.69% |
| Foreign Exchange rate Adjustments | -200.00% | 66.32% | -76.94% | 549.69% | 247.28% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -448.89% | 815.69% | 107.89% | -86.55% | 53.62% |